RxDoctor Payments Data

Megan Self

Family · Gastonia, NCNPI 1538624317

Payments from drug & device makers

$7,888in general payments, 2019–2025

Across 389 payments — averaging $20.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • GSK$912
  • Novo Nordisk$669
  • Regeneron Healthcare Solutions, Inc.$573
  • Boehringer Ingelheim$506
  • Lilly USA, LLC$485
  • plus $4K from 44 others

What the payments were for

  • Food & beverage$7,78899%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,888 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$33,537
Medicare patients
244
Services billed
399

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter95$75,338
Breztri AerosphereBudesonide/Glycopyr/Formoterol50$37,394
Breo ElliptaFluticasone/Vilanterol35$20,670
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr34$15,606
Stiolto RespimatTiotropium Br/Olodaterol Hcl21$13,572
SymbicortBudesonide/Formoterol Fumarate38$10,889
Albuterol Sulfate HfaAlbuterol Sulfate284$7,467
Fluticasone-SalmeterolFluticasone Propion/Salmeterol38$6,112
Incruse ElliptaUmeclidinium Bromide11$5,224
Arnuity ElliptaFluticasone Furoate11$2,307
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$1,872
Ventolin HfaAlbuterol Sulfate31$1,808
Wixela InhubFluticasone Propion/Salmeterol16$983
Ropinirole Hcl43$900
Modafinil19$838

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$912$119,146186 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,202$48,28288 claims
Boehringer IngelheimStiolto Respimat$506$13,57221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.

Other family in Gastonia

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →